News

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, according to recent research.

Nicox and Kowa entered into an agreemen in February 2024, in which Kowa was granted exclusive Japanese rights to develop and commercialize NCX 470.

Can AI compete with the well-oiled machine of the contemporary clinic?

Matthew Starr, MD, discusses techniques for correcting astigmatism in patients lacking capsular support, enhancing visual outcomes surgery.

Enhanced screenings and a unified registry could save vision and lives

Dr. Nimesh A. Patel reveals key findings on pegcetacoplan and anti-VEGF treatments for geographic atrophy and neovascular AMD at ASRS 2025.

The planned acquisition of STAAR includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia with or without astigmatism.

Ophthalmology celebrates 50 years of groundbreaking innovations, highlighting anti-VEGF therapies, OCT imaging, and future advancements in eye care.

Avant Technologies and Ainnova Tech refine clinical trial protocol for Vision AI platform, aiming for FDA 510(k) approval to enhance diabetic retinopathy detection.

The Portal study is a long-term extension of the phase 3 Archway study

Genentech reveals five-year data showing Susvimo effectively maintains vision in wet AMD patients with fewer injections, offering a promising treatment alternative.

TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA

4D-150 is an investigational agent designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

The solution was approved by the US Food and Drug Administration in late May 2025.

RTP-008 features sustained immunosuppressant delivery for long-term therapeutic effects.

Clearside Biomedical secures Health Canada approval for Xipere, while exploring strategic options to enhance its suprachoroidal delivery platform and pipeline.

Justis Ehlers, MD, FASRS, presented "PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy," during the 2025 ASRS meeting held in Long Beach, California.

Jay Chhablani, MD, presented the phase 1/2 clinical trial data for OCU410, at the 2025 annual meeting of the American Society of Retina Specialists.

Steven D. Ness, MD, discusses his research on vitamin D's role in reducing complications after retinal surgery at ASRS 2025.

Catch up on this week's highlights in retina.